Differential effects of predosing on tumor and tissue uptake of an 111in-labeled anti-TENB2 antibody-drug conjugate

Journal of Nuclear Medicine

Volumn 53, Issue 9, 2012, Pages 1454-1461

  Boswell, C Andrew ^a   Mundo, Eduardo E ^a   Zhang, Crystal ^a   Stainton, Shannon L ^a   Yu, Shang Fan ^a   Lacap, Jennifer A ^a   Mao, Weiguang ^a   Kozak, Katherine R ^a   Fourie, Aimee ^a   Polakis, Paul ^a   Khawli, Leslie A ^a   Lin, Kedan ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody drug conjugates; Predosing; Prostate cancer; SPECT CT imaging; Tissue distribution

Indexed keywords

ANTIBODY CONJUGATE; IBRITUMOMAB TIUXETAN; INDIUM 111; MEMBRANE PROTEIN; PROTEOGLYCAN; TENB2 PROTEIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; COMPUTER ASSISTED TOMOGRAPHY; EXPLANT; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MALE; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84866170999     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.103168     Document Type: Article

References (40)

1. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
2. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
3. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154-169.
4. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064-6072.
5. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. 1992;52:637-642.
6. Schlom J, Milenic DE, Roselli M, et al. New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma. Int J Rad Appl Instrum B. 1991;18:425-435.
7. Wahl RL, Wilson BS, Liebert M, Beierwaltes WH. High-dose, unlabeled, non-specific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts. Cancer Immunol Immunother. 1987;24:221-224.
8. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
9. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
10. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
11. Kletting P, Meyer C, Reske SN, Glatting G. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm. 2010;25:279-287.
12. Glynne-Jones E, Harper ME, Seery LT, et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer. 2001;94:178-184.
13. Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther. 2004;3:921-932.
14. Lin K, Taylor JR Jr, Wu TD, et al. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS ONE. 2011;6:e18608.
15. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925-932.
16. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784.
17. Lin K, Lou T, Ferl G, et al. Cross-species pharmacokinetic characterization of antibody drug conjugate TenB2-vc-E to understand target biology. AAPS Meeting Abstracts. 2009; Los Angeles, CA.
18. Boswell CA, Mundo EE, Firestein R, et al. An integrated approach to identify normal tissue expression of targets for antibody drug conjugates: case study of TENB2. Br J Pharmacol. In press.
19. Boswell CA, Mundo EE, Zhang C, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22:1994-2004.
20. Pastuskovas CV, Mundo EE, Williams SP, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012;11:752-762.
21. Corey E, Vessella RL. Xenograft models of human prostate cancer. In: Chung LWK, Isaacs WB, Simons JW, eds. Contemporary Cancer Research: Prostate Cancer: Biology, Genetics, and the New Therapeutics, 2nd ed. Totowa, NJ: Human Press; 2007:3-31.
22. Koochekpour S, Zhuang YJ, Beroukhim R, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer. 2005;44:351-364.
23. Boswell CA, Ferl GZ, Mundo EE, et al. Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm. 2010;7:1848-1857.
24. Quayle SN, Sadar MD. A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics. 2006;87:633-637.
25. Boswell CA, Ferl GZ, Mundo EE, et al. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS ONE. 2011;6:e17874.
26. Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol. 2010;7:31-38.
27. Shepard DR, Raghavan D. Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol. 2010;7:13-21.
28. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002;17:359-370.
29. Sharkey RM, Burton J, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol. 2005;1:47-62.
30. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50:444-453.
31. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood. 2009;113:3891-3895.
32. Strickland LA, Ross J, Williams S, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol. 2009;218:380-390.
33. Davies Q, Perkins AC, Roos JC, et al. An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br J Obstet Gynaecol. 1999;106:31-37.
34. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(suppl 1):128S-140S.
35. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112:830-835.
36. 131Irituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412-1421.
37. Illidge T, Du Y. When is a predose a dose too much? Blood. 2009;113:6034-6035.
38. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res. 1999;5:51-60.
39. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757-778.
40. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res. 2008;14:2171-2179.